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Abstract
Background: There is no recommendation to screen ferritin level in blood donors, even though
several studies have noted the high prevalence of iron deficiency after blood donation, particularly
among menstruating females. Furthermore, some clinical trials have shown that non-anaemic
women with unexplained fatigue may benefit from iron supplementation. Our objective is to
determine the clinical effect of iron supplementation on fatigue in female blood donors without
anaemia, but with a mean serum ferritin ≤ 30 ng/ml.
Methods/Design: In a double blind randomised controlled trial, we will measure blood count and
ferritin level of women under age 50 yr, who donate blood to the University Hospital of Lausanne
Blood Transfusion Department, at the time of the donation and after 1 week. One hundred and
forty donors with a ferritin level ≤ 30 ng/ml and haemoglobin level ≥ 120 g/l (non-anaemic) a week
after the donation will be included in the study and randomised. A one-month course of oral
ferrous sulphate (80 mg/day of elemental iron) will be introduced vs. placebo. Self-reported fatigue
will be measured using a visual analogue scale. Secondary outcomes are: score of fatigue (Fatigue
Severity Scale), maximal aerobic power (Chester Step Test), quality of life (SF-12), and mood
disorders (Prime-MD). Haemoglobin and ferritin concentration will be monitored before and after
the intervention.
Discussion: Iron deficiency is a potential problem for all blood donors, especially menstruating
women. To our knowledge, no other intervention study has yet evaluated the impact of iron
supplementation on subjective symptoms after a blood donation.
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Background
Clinical trials have shown that non-anaemic women with
unexplained fatigue may benefit from iron supplementa-
tion [1-5]. A one-month ferrous sulphate treatment
showed positive effects on fatigue in women with a mean
serum ferritin of 30 ng/ml [5]. Improved aerobic capacity,
assessed by VO2max, has also been associated with iron
supplementation in women with non-anaemia iron defi-
ciency [6].
The haemoglobin content of a whole-blood donation
(450 ml) is around 55 g to 70 g, and the iron content is
around 187 mg to 283 mg. This iron amount corresponds
to a range of 66% to 97% of the total stored iron in an
average menstruating woman. According European Coun-
cil directives, it is not mandatory to measure the donor's
ferritin level before a blood donation. However, to avoid
iron deficiency anaemia induced by blood donations,
women's haemoglobin level is controlled, and their blood
donation frequencies are limited to three or four per year.
According to a recent survey, 11% of female and 4% of
male blood donors complained from fatigue after a dona-
tion [7]. The greater proportion of haemoglobin, which is
removed from women who are smaller in size and have
higher prevalence of iron deficiency, can probably explain
the gender difference. Moreover, fatigue is the third com-
plication following a blood donation, after bruise and
sore arm. This has an adverse impact on blood donations.
Fatigue was associated with a 20% reduction in blood
donor return rates at one year post donation [8].
Two recent trials have also shown that a short period of
ferrous sulphate supplementation decreased the inci-
dence of iron deficiency in blood donors [9,10]. Further-
more, it produced a rapid improvement in haemoglobin
level between blood donations, which improved the fidel-
ity of donors [10]. To our knowledge, no study has shown
the impact of iron supplementation on female blood
donors' symptoms, such as fatigue.
Method/Design
Objectives
Our primary objective is to test the hypothesis that a one-
month iron supplementation (oral ferrous sulphate, 80
mg/day of elemental iron), after blood donation, has pos-
itive effects on symptoms of fatigue in women blood
donors with a serum ferritin concentration ≤ 30 ng/ml,
and no anaemia.
Secondary objectives are to assess the effect of treatment
on aerobic capacity, mood, quality of life, and haemato-
logical parameters.
Primary outcomes
We will assess changes in self-reported fatigue at one-
month follow-up. The self-reported fatigue will be meas-
ured using a 10 cm visual analogue scale (VAS), which has
demonstrated good psychometric properties in this con-
text [11].
Secondary outcomes
We will assess changes in fatigue, mood disorders, and
quality of life [11-13], using a self-administered question-
naire; changes in maximal aerobic power (estimated by
the Chester Step Test) [14]; changes in serum ferritin and
haemoglobin; and adherence to treatment.
Design
Our study will be a pragmatic randomised placebo con-
trolled trial. Donors will join the study and sign an
informed consent before blood donation. Approximately
450 ml of venous blood will be collected (not used for the
study) within a blood pack set (NGR6449B, Fenwal, Bel-
gium), which allow a predonation sampling of an excess
12 ml for further testing in our study. One week after, vol-
unteers with a concentration of ferritin ≤ 30 ng/ml, and a
concentration of haemoglobin ≥ 120 g/l, will be included
in the study and randomised to receive either ferrous sul-
phate (80 mg/day of elemental iron) or placebo for four
weeks (See Figure 1).
Setting
This randomised controlled trial will take place at the Uni-
versity Hospital of Lausanne. The blood donation will
take place in the Blood Transfusion Service, and the fol-
low-up in the Department of Ambulatory Care and Com-
munity Medicine.
Study participants
Study participants will be recruited among women com-
ing spontaneously to the Blood Transfusion Service to
donate blood. Donors aged 18 yr – 50 yr and eligible to
donate blood, according to the blood donation eligibility
guidelines of the Swiss Transfusion Service, will be consid-
ered for inclusion. Exclusion criteria are psychiatric condi-
tions or diseases that render the participant unable to give
consent; thyroid, hepatic, rheumatic, kidney, cardiopul-
monary, or intestinal disease; acute or chronic inflamma-
tion, diabetes, hemochromatosis, pregnancy, and medical
treatment that could perturb iron absorption.
Randomisation, allocation and masking of the 
study
A physician working at the Blood Transfusion Service will
be responsible for seeing all potential participants (i.e.,
female donors aged 18 yr – 50 yr) and will assign the next
available study number. Once eligibility criteria for a
blood donation is fulfilled and an informed consent isTrials 2009, 10:4 http://www.trialsjournal.com/content/10/1/4
Page 3 of 6
(page number not for citation purposes)
obtained, blood donation will be performed. The ran-
domisation will take place a week after the blood dona-
tion with the following criteria for inclusion.
Haemoglobin level ≥ 120 g/l, ferritin level ≤ 30 ng/ml.
Randomisation will take place at an independent phar-
macy, according to a pre-established computer-generated
list using simple randomisation. Each drug package will
be coded with a unique number according to the ran-
domisation schedule. The codes will be held by the phar-
macist and remained unbroken until the analyses are
completed. A research assistant responsible for seeing the
blood donors will allocate the next available treatment
pack in a telephone call to the pharmacist. Patients, car-
egivers, and assessors will be blinded to treatment assign-
ment until the end of the trial. Participants will remain on
the same allocation throughout the study (intention-to-
treat protocol). An electronic device that assesses adher-
ence to treatment will also be delivered. The pills and elec-
tronic device will have the identical appearance for the
experimental and placebo groups. The iron supplement
and the placebo will have the same taste.
Treatment
Volunteers will receive either 80 mg/day oral ferrous sul-
phate (Tardyferon, Robapharm, Boulogne, France) or pla-
cebo for four weeks. To decrease side effects, the pills will
be taken during breakfast. Currently, oral ferrous sulphate
is the reference treatment for iron deficiency without
flow chart Figure 1
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anaemia. Oral ferrous sulphate is resorbed mainly in the
duodenum and proximal jejunum. Iron resorption
depends directly on the level of hepcidin. Described side
effects are upset stomach, constipation, diarrhoea, nausea,
and black or dark-coloured stools. No serious complica-
tions have been reported. However, uncommon cases of
allergic reactions have been described. Volunteers will be
asked not to take over the counter vitamin or iron supple-
ments.
Measurements
Paramedical staff will collect data. Ten cm visual analogue
scales, ranging from "no fatigue at all" to "very severe
fatigue," associated with another self administered ques-
tionnaire focusing on fatigue (Fatigue Severity Scale, [11])
will be completed at randomisation (D0), and after the
experimental phase (D28). The initial questionnaire has
been translated into French and back translated for verifi-
cation. The appropriateness and acceptability of the ques-
tions have been tested in our setting in pilot studies. For
additional outcomes, depression and anxiety symptoms
will be assessed using the Prime-MD questionnaire [13].
Health-related quality of life will be measured using the
SF-12 questionnaire [12]. An evaluation of the amount of
menstrual blood loss (Pictorial Bleeding Assessment
Chart, [15]) will also be performed at baseline to detect
any possible hypermenorrhea.
Complete blood count and ferritin concentration will be
measured at D-7 (day minus 7), D0 and D28. C-reactive
protein (CRP), an acute phase protein, will be analysed at
D0 to identify volunteers whose ferritin concentration
might be falsely elevated by occult infection or inflamma-
tion. Complete blood count will be measured using the
Sysmex XE 2100 (Roche) haematology analyser. Ferritin
and CRP will be measured by immunoturbidimetry.
To assess the change in aerobic capacity at baseline (D0)
and after iron treatment (D28), a step test (Chester Step
Test) will be carried out. Measurements obtained with this
protocol have been demonstrated to give excellent test-
retest reliability, and are highly correlated with VO2max (r
= 0.92) [14].
Adherence to treatment will be measured by an electronic
device, Medication Event Monitoring System (MEMS; Aar-
dex Europe, Switzerland), which records the date and time
that the pill container is opened [16]. Questions will be
asked at D28 to evaluate whether the electronic monitor-
ing was properly used (for example, if each opening is cor-
related with the consumption of one pill). Unused pills
will also be counted. Adherence will be quantified by
dividing the number of times the device was opened by
the total number of days of observation. A study that used
this system has shown that compliance and motivation to
take the treatment were improved [17].
The success of blinding will also be evaluated in the ques-
tionnaire at D28. Serious adverse events will be reported
to the principal investigator within 48 hr, and will be
recorded in follow-up notes.
Statistical methods
Sample size
The main outcome variable is the level of fatigue at one
month. The sample size for randomised volunteers was
calculated using a two-sample comparison of means to
detect a one point difference between the groups on the
visual analogue scale, similar to the minimal clinically
appreciable difference for pain [18]. According to a previ-
ous study [5], we can expect a standard deviation of two
points. For a two-tailed test (α = 0.05, power = 0.80), each
group should include 63 participants. Anticipating a 10%
dropout rate, the total sample size is rounded to 140 par-
ticipants.
Statistical analysis
Analysis will be conducted on an intention-to-treat basis.
The measure of effect is the change in fatigue level. The
null hypothesis is that there will be no difference in
fatigue VAS scores between the experimental and control
groups at 28 days, adjusted for the baseline level of fatigue
on the same scale. The significance level will be set at 5%,
using a linear regression with the treatment group, and
using the baseline values of fatigue as independent varia-
bles, and using fatigue levels at 28 days as the dependent
variables. The measure of effect for the secondary out-
comes will be assessed by the same method. If ferritin lev-
els are not normally distributed, a transformation will be
used. All calculations will be performed with StataCorp
2008, Statistical Software: Release 10.0, Stata Corpora-
tion, College Station, Texas.
Missing data and drop-outs
Missing data will be handled using multiple imputation.
Reasons for dropping out will be compared between the
placebo and the ferrous sulphate groups at a significant
level of 0.05. In the intention-to-treat analysis, dropouts
will be considered as missing data and analysis will use
multiple imputation to interpret the results.
Ethical aspects
The study was approved in July 2008 by the University of
Lausanne Ethics Committee for clinical research. The
main risk for participants is developing anaemia after the
blood donation. The blood test a week after blood dona-
tion will permit diagnosis of this complication, and anae-
mic volunteers will be removed from the study before
randomisation. In this case, a doctor from the BloodTrials 2009, 10:4 http://www.trialsjournal.com/content/10/1/4
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Transfusion Service will introduce a three-month ferrous
sulphate treatment and inform the individual's general
practitioner. Another type of risk that may be encountered
by volunteers is due to side effects of the treatment. As
documented above, side effects of ferrous sulphate are
well documented and tolerated by a majority of treated
patients. Finally, there is no risk of inducing an iron over-
load in volunteers because only donors with a ferritin
level ≤ 30 ng/ml will receive the treatment.
Forecast execution dates
We plan to enrol the first donor in November 2008, and
the last in March 2009. The study of the last donor should
be complete in July 2009, and publication is planned for
July 2010.
Discussion
Iron is an essential nutrient for human cells, which blood
donors lose with each donation. Menstruating women are
particularly at risk for iron depletion, even before blood
donation. Actually, recommendations in force for blood
donation do not include screening of ferritin levels of reg-
ular donors to ensure that their iron balances are not neg-
ative. Also, there is no difference in approach to women of
childbearing age and to postmenopausal women, in terms
of donation frequency or short-term iron substitution.
Studies have shown that iron-deficiency anaemia is asso-
ciated with fatigue, which can be partially reversed with
iron treatment [1-5]. Moreover, iron supplementation to
blood donors has been studied [9,10]. However, out-
comes of those trials stressed only the return rates of
donors, and improving ferritin or haemoglobin levels at
the time of the next donation.
The strength of the present study is that, to our knowl-
edge, this is the first randomised controlled trial that tests
iron supplementation efficacy on subjective symptoms,
and that measures results during the time between two
donations. If our hypothesis is confirmed, ie that post-
donation iron supplementation can relieve adverse sub-
jective symptoms related to iron deficiency without anae-
mia, management of blood donors should be revisited.
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